Ohm, I would suggest you do more DD on MTNB.
$30M was just invested in this company by prominent biopharma institutional investors, NIH is running and paying for clinical trials of one of its drugs, another drug handily beat EPA approved Vascepa in a head to head clinical trial, and its nano lipid crystal platform is being tested by BP on its drugs, which could lead to lucrative licensing deals.
The MTNB BOD is comprised a former FDA head, prominent biopharm investors, and top executives from companies such as Amgen and Roche.
MTNB's SP has doubled over the past six months, and analyst estimates are many times higher than the current SP.
Check back in a year, and my guess is the SP will be much higher than it is today.
As for the CEO, Jerry Jabbour, I would suggest you watch some of his interviews, as he comes across as credible, competent, and knowledgeable, everything our CEO is not.
LM